[1]
|
Grigsby PW,Winter K,Wasserman TH,et al.Irradiation with or without misonidazole for patients with stages ⅢB and IV A carcinoma of the cervix:final results of RTOG 80-05[J].Int J Radiat Oncol Biol Phys,1999,44(3):513-517. |
[2]
|
Siim BG,Menke DR,Dorie MJ,et al.Tirapazamine-induced cytotoxicity and DN A damage in transplanted tumors:relationship to tumor hypoxia[J].Cancer Res,1997,57:2922-2928. |
[3]
|
Brown JM.The hypoxtc cell:a target for selective cancer therapy-eighteenth Bruce F.Cain Memorial Award lecture[J].Cancer Res,1999,59:5863-5870. |
[4]
|
Shulman LN,Busmell L,Riese N,et al.Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors[J].Int J Radiat Oncol Biol Phys,1999,44(2):349-353. |
[5]
|
Lee D-J,Trotti A,Spencer S,et al.Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas:a Phase Ⅱ study[J].Int J Radiat Oncol Biol Phys,1998,42:811-815. |
[6]
|
Mitchell JB,Cook JA,Krishna MC,et al.Radlation sensitisation by nitric oxide releasing agents[J].Br J Cancer,1996,74(Suppl.27):S 181-S 184. |
[7]
|
Griffin RJ,Wakepeace CM,Hur W J,et al.Radiosensitization of hypoxic tumor cells in vitro by nitric oxide[J].Int J Radiat Oncol Biol Phys,1996,36:377-383. |
[8]
|
Verovski VN,Van den Berge DL,Soete GA,et al.Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside[J].Br J Cancer,1996,74:1734-1742. |
[9]
|
Janssens M Y,Verovski VN,Van den Berge DL,et al.Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation[J].Br J Cancer,1999,79:1086-1089. |
[10]
|
Jordan BF,Misson P,Demeure R,et al.Changes in tumor oxygenation/perfusion induced by the NO donor,isosorbide dinitrate,in comparison with carbogen:monitoring by EPR and MRI[J].Int J Radiat Oncol Biol Phys,2000,48(2):565-570. |
[11]
|
Khandelwal SR,Kavanagh BD,Lin P-S,et al.RSR 13,an allosteric effector of haemoglobin,and carbogen radiosensitize FSaⅡ and SCCVⅡ tumours in C3H mice[J].Br J Cancer,1999,79:814-820. |
[12]
|
Teicher BA,Ara G,Emi Y,et al.RSR13:effects on tumor oxygenation and response to therapy[J].Drug Dev Res,1996,38:1-11. |
[13]
|
Kavanagh BD,Khandelwal SR,Schmidt-Ullrich RK,et al.A phase IB study to evaluate repeated daily intravenous doses of RSR13 administered to cancer patients receiving concurrent radiation therapy[J].Int J Radiat Oncol Biol Phys,1997,39:330S. |
[14]
|
Young SW,Qine F,Harriman A,et al.Gadolinium(Ⅲ) texaphyrin:a tumor selective radlation sensitizer that is detectable by MRI[J].Proc Natl Acad Sci USA,1996,93:6810-6615. |
[15]
|
Miller RA,Woodburn K,Fan Q,et al.In vivo animal studies with Gadolinium(Ⅲ) texaphyrin as a radiation enhancer[J].Int J Radiat Oncol Biol Phys,1999,45(4):981-989. |
[16]
|
Sessler JL,Miller RA.Texaphyrins:new drugs with diverse clinical applications in radiation and photodynamic therapy[J].Biochem Pharmacol,2000,59(7):733-739. |
[17]
|
Bernhard EJ,Mitchell JB,Deen D,et al.Re-evalnating gadolinium(Ⅲ)texaphyrin as a radiosensitizing agent[J].Cancer Res,2000,60(1),86-91. |
[18]
|
Lawrence TS,Eisbruch A,McGinn CJ,et al.Radiosensitization by gemcitabine[J].Oncology,1999,13(10 suppl.5):55-60. |
[19]
|
Ezekiel MP,Robert F,Meredith RF,et al.Phase I study of anti-epidermal growth factor receptor antibody c225 in combination with irradiation inpatients with advanced squamous cell carcinoma of the head and neck[J].Proc Am Soc Clin Oncol,1998,17:395a. |
[20]
|
Wouters BG,Brown JM.Cells at intermediate oxygen levels can be more important than the "hypoxicfraction" in determining tumor response to fractionated radiotherapy[J].Radiat Res,1997,147:541-550. |